Fig. 2.

TLR agonists do not enhance the number of adoptively transferred T cells in lymph nodes or the tumor microenvironment. Flow cytometry was used to quantify pMel T cells in the tumor microenvironment, as described in “Materials and methods”. a Delivery of TLR agonists in combination with adoptive T-cell transfer did not increase the number of pMel T cells in tumor-draining lymph nodes and coincided with reductions in their number in b nondraining LNs (*P ≤ 0.01, days 1 and 7, relative to ‘T-cells alone’) and c s.c. tumors (**P = 0.005, relative to ‘T-cells alone’). c The incidences of host CD8⁺ T cells and CD45⁺ leukocytes in the tumor site were not altered as a result of therapy. Data were compiled from 3 independent experiments, n = 6–9 at each timepoint; P values calculated using the Mann–Whitney test